Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pharmion planning platinum-based prostate cancer drug

Pharmion planning platinum-based prostate cancer drug

3rd March 2006

Pharmion says it is planning to use a platinum-based drug in its treatment of prostate cancer.

The drug manufacturer is hoping to receive the go-ahead from the European Medicines Authority (EMEA) to use satraplatin for the treatment of second-line hormone refractory prostate cancer from the beginning of next year.

It is the only oral platinum based treatment that is currently in the advanced stages of clinical development.

“We are committed to providing the submission to the EMEA in as timely a fashion as possible, pending the results from a final analysis,” said Patrick Mahaffy, Pharmion’s president and chief executive.

It is hoped the drug will also be used in the treatment of a number of other illnesses.

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.